Sponsors (2)
The bill expands nationwide telehealth access to psychiatric care and controlled‑substance treatment — improving care availability, especially for rural and underserved patients and reducing provider administrative barriers — while shifting oversight away from states toward a federal/corporate framework that raises risks of diversion, reduced local control, market concentration, and new compliance costs.
People with mental‑health conditions, opioid use disorder, and other chronic conditions — including those in rural and underserved areas — can obtain psychiatric care and controlled‑substance medications via telehealth (including across state lines), improving access, continuity of care, and appointment availability.
Healthcare providers working for telehealth organizations face reduced administrative barriers — streamlined DEA-related cross‑state prescribing rules, ability to list a telehealth entity as primary practice location, and interstate malpractice coverage recognition — simplifying credentialing and enabling more clinicians to offer remote care.
The bill requires telehealth entities to meet staffing, accreditation, and monitoring standards and limits compensation tied to visit volume, which should raise the quality and safety of remote prescribing and reduce perverse incentives.
Expanding cross‑state teleprescribing and preempting state constraints increases the risk of inappropriate prescribing, medication diversion, and weakened local oversight, potentially harming patients and communities.
State governments lose regulatory authority and enforcement tools over controlled‑substance prescribing and telepsychiatry, limiting their ability to set stricter, locally tailored protections and to discipline or monitor out‑of‑state clinicians.
Designating telehealth entities as practitioners' principal place of business and enabling corporate platforms to centralize operations may concentrate prescribing authority, reduce accountability, and complicate oversight of corporate telehealth providers.
Based on analysis of 5 sections of legislative text.
Introduced January 9, 2026 by Neal Patrick Dunn · Last progress January 9, 2026
Expands federal rules to make many controlled‑substance prescriptions issued after telehealth evaluations valid nationwide, creates detailed definitions and standards for telehealth practitioners and telehealth entities, and limits states from blocking these activities. It bars pharmacists from refusing to fill controlled‑substance prescriptions solely because they were issued via telehealth (subject to limited validation steps) and authorizes civil penalties for refusals. Also exempts certain telehealth encounters from separate DEA registration requirements, allows psychiatrists licensed in one State to provide telepsychiatry to patients in other States when requirements are substantially similar, and preempts conflicting State laws so federal rules control where they conflict with State restrictions.